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httpCase: A 73 year old patient with a longstanding history of peripheral artery occlusive disease (PAOD) presented
with an acute on chronic progression of symptoms, based on a long occlusion of the superﬁcial femoral artery
(SFA), which was treated by thrombosuction, percutaneous transluminal angioplasty, and SFA stenting. Post-
procedural dual antiplatelet therapy was initiated and subsequently adjusted based on platelet reactivity testing.
Discussion: Increasingly complex arterial lesions are treated by an endovascular approach; however, long-term
patency rates are often disappointing. In order to optimize the patency rates (dual) antiplatelet therapy is
initiated. It is known that a substantial proportion of patients have high platelet reactivity despite the use of
antiplatelet drugs. Several methods have been published to test the individual response to different antiplatelet
drugs. There is evidence that adjusting antiplatelet therapy based on platelet reactivity testing results in a
reduction of cardiovascular events and bleeding complications; however, the optimal test and the exact role of
personalized antiplatelet therapy in PAOD is currently unknown.
Conclusion: Although some important hurdles should be overcome before routine implementation, the concept
of post-procedural antiplatelet therapy in patients with PAOD is advocated in order to optimize the results of
endovascular interventions, as apparent from the presented case.
 2015 The Authors. Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A 73 year old male with acute progression of chronic pe-
ripheral artery occlusive disease (PAOD) Rutherford stage 5,
visited the outpatient clinic of a tertiary vascular referral
center. The patient had a medical history of kidney trans-
plantation, stage 3 chronic kidney disease (CKD), deep
venous thrombosis complicated by a pulmonary embolism,
and intermittent claudication for which he had undergone
stenting of both common iliac arteries 10 years earlier and
had been prescribed aspirin. A digital subtraction angiog-
raphy (DSA) was performed, which revealed a 23 cm long
occlusion of the superﬁcial femoral (SFA) and proximal
anterior tibial artery (Fig. 1A). Thrombosuction (AngioJet,
Boston Scientiﬁc, Marlborough, MA, USA) and subsequent
percutaneous transluminal angioplasty (PTA) of the SFAese authors contributed equally to this work.
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://dx.doi.org/10.1016/j.ejvssr.2015.09.003were performed (Fig. 1B). Because of multilevel residual
stenoses, three self expandable stents and a balloon
expandable stent were placed in the SFA over a total length
of 27 cm with satisfactory results (no residual stenosis
>30%). After the procedure, dual antiplatelet therapy
(DAPT) was initiated: clopidogrel (loading dose 300 mg) was
added to the aspirin. The next day a VerifyNow P2Y12 assay
(Accumetrics, San Diego, CA, USA) and a CYP2C19 poly-
morphism DNA test (Spartan RX CYP2C19, Spartan Biosci-
ence Inc., Ottawa, Canada) were performed, which showed
0% platelet inhibition and two loss of function CYP2C19
alleles, respectively, which suggested that clopidogrel was
not effective. Therefore, clopidogrel was switched to the
stronger P2Y12 inhibitor, prasugrel. A VerifyNow showed an
effective platelet inhibition on prasugrel (41% inhibition,
PRU 171). At the 6 month follow up the patient did not
report any pain, and duplex ultrasound conﬁrmed patency
of the stents without restenosis.Endovascular revascularization
Nowadays, minimally invasive endovascular techniques are
often the ﬁrst line of therapy in PAOD. The choice of the
speciﬁc endovascular technique depends on various factors,
Figure 1. (A) Digital subtraction angiography (DSA), which shows a 23 cm occlusion in the superﬁcial femoral artery. (B) DSA after two
thrombosuctions with the Angiojet catheter. (C) DSA after percutaneous transluminal angioplasty and stenting.
12 S.M.O. Peeters Weem et al.such as the cause, length and degree of stenosis or occlu-
sion, and the duration of the occlusion. Mechanical
thrombectomy or thrombosuction is most effective in
removing fresh thrombi, causes minimal peripheral embo-
lization, and is less time consuming than medicinal throm-
bolysis.1 PTA is usually the preferred choice in limited
disease such as stenosis or occlusions up to 10 cm in length
and stenting is advised when there is a residual stenosis of
30e50% or a ﬂow limiting dissection.2,3
One year primary patency rates of balloon angioplasty in
long femoral occlusions vary from 27% to 43.5%,4 which is
improved by the use of drug eluting balloons (primary
patency up to 76.1%).5 Primary patency at 1 year for
stenting of long femoral occlusions varies from 64.8% to
66% and secondary patency rates vary between 70% and
83%, which depends on the characteristics of the athero-
sclerotic lesion and type of stent.5e8 Because of the acute
on chronic presentation in the current case, due to a total
and likely recent occlusion of the SFA, mechanical throm-
bectomy followed by PTA and stenting due to residual
multilevel stenosis was chosen.Post-procedural antiplatelet therapy
The fast and continuous evolution of endovascular tech-
nologies allows for successful revascularization of increas-
ingly complex atherosclerotic lesions. Lifelong antiplatelet
therapy (APT) is generally recommended to promote
patency after peripheral endovascular interventions of the
femoropopliteal segment, although no evidence based
guidelines exist.1 Nowadays, many different types of anti-
platelet regimen are used (Table 1). Studies on APT inpatients with PAOD have major limitations due to small
study populations and potential risk of bias.9 This lack of
high quality evidence leads to a great (inter)national variety
in the administered APT, duration of treatment, and platelet
reactivity test used to assess the effect of APT.10 In cardi-
ology trials, a relative risk reduction of secondary cardio-
vascular events (cardiovascular death, myocardial infarction
or any revascularization) of around 30% is seen when
adding clopidogrel to aspirin after percutaneous coronary
intervention (PCI).11e13 It is not known exactly whether this
is the case in PAOD; however, a similar risk reduction is
assumed.
Prior to PTA and stenting of femoropopliteal arteries, a
loading dose of clopidogrel is often added to aspirin, and
DAPT is continued for 1e3 months after PTA. The rationale
for this practice is largely based on extrapolation of data
derived from percutaneous coronary interventions (PCIs),
and is not supported by international guidelines.1,14
The patient in this case received a loading dose of 300 mg
of clopidogrel after the procedure followed by a mainte-
nance dose of 75 mg once daily for 6 months. Several
recent cardiology trials suggest that a loading dose of
600 mg might be more effective in preventing major
adverse cardiac events, without increasing the risk of
bleeding.15 However, for PAOD patients there is no evi-
dence that suggests superiority of a higher loading dose.
Analogous with observations in patients undergoing PCI,
a natural variation in response to APT can be expected
among patients undergoing peripheral revascularization. A
recently published review showed that high on aspirin
platelet reactivity (HAPR) occurred in 22.2% of the patients
in a pooled analysis of 102 studies containing a total of
Table 1. Different types of antiplatelet regimens.
Class Drugs Mechanism of action Pros Cons
Cyclo-oxygenase
inhibitors
Aspirin
Carbasalate
calcium
Triﬂusidal
Irreversibly inhibits the enzyme COX,
resulting in reduced platelets production
of thromboxane A2 (powerful
vasoconstrictor that lowers cyclic AMP and
acts as secondary platelet activator)
Economical
Also analgesic, anti-inﬂammatory
and antioxidant properties
Risk of gastrointestinal bleeding
Resistance
P2Y12 inhibitors
(Thienopyridines)
Clopidogrel Binds irreversibly to the ADP receptors
(P2Y12 receptors), ensuring a inhibition of
the ADP pathway
Prodrug that needs to be metabolized via
the CYP by the liver
Economical Requires CYP2C19 for its metabolization
Slow onset of action
Inter-individual variability
Prasugrel Same mechanism of action as clopidogrel/
ticlopidine
Needs transformation to an active
metabolite via the CYP system in a similar
manner to clopidogrel
Faster onset of action than clopidogrel
No effect of CYP2C19 genotype on clinical
cardiovascular event rates
Increased bleeding risk in patients >75
years, <60 kg and/or with CVA/TIA in
medical history
More expensive than clopidogrel
Ticlopidine Same mechanism of action as clopidogrel/
prasugrel
Suitable when aspirin has failed or is not
tolerated.
Rare, but serious side effects of
neutropenia and TTP
P2Y12 inhibitors
(Nucleotide
analogues)
Ticagrelor Reversible P2Y12 receptor antagonists.
Unlike the thienopyridines, ticagrelor is
not a prodrug and does not require
metabolic activation
More effective than thienopyridines in
prevention of vascular death, MI, or stoke
Twice daily administration
Increased bleeding risk
Cangrelor Same mechanism of action as ticagrelor Fast acting drug, suitable for bridging
surgery patients who require P2Y12
inhibition
IV administration
Phosphodiesterase
inhibitors
Cilostazol Inhibits phosphodiesterase enzymes that
break down cAMP, (resulting in increasing
cellular cAMP levels and thereby blocking
of platelet aggregation response to ADP)
and/or cGMP
Effective in increasing pain free walking
distance in patient with CI
Dangerous with heart failure
Dipyridamole Same mechanism of action as cilostazol Effects of dipyridamole and aspirin on
platelet behaviour are additive
High dose causes vasodilatation
Twice daily administration
Glycoprotein IIb/IIIa
inhibitors
Abciximab
Eptiﬁbatide
Tiroﬁban
Blocks GPIIb/IIIa, the platelets receptor for
ﬁbrinogen and von Willebrand factor
Rapid onset of action IV administration
ADP ¼ adenosinediphosphate; cAMP ¼ cyclic adenosine monophosphate; cGMP ¼ Cyclic guanosine monophosphate; CI ¼ claudication intermittens; COX ¼ cyclo-oxygenase inhibitors;
CVA ¼ cerebrovascular accident; CYP ¼ cytochromes P450; GPIIb/IIIa ¼ glycoprotein IIb/IIIa; IV ¼ intravenous; TIA ¼ transient ischemic accident; TTP ¼ thrombotic thrombocytopenic
purpura.
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14 S.M.O. Peeters Weem et al.44,098 patients with coronary artery, cerebrovascular, or
peripheral arterial disease who had been treated with
aspirin with or without clopidogrel.16 Patients with HAPR
had an increased risk of future cardiovascular events
(combined endpoint of cardiovascular death, myocardial
infarction, stent thrombosis, stroke, acute limb ischemia,
peripheral revascularization, and acute peripheral occlu-
sion; RR 2.09, 95% CI 1.77e2.47). The number of non-
responders for clopidogrel was even higher: 40.4% of pa-
tients were diagnosed with high on clopidogrel platelet
reactivity (HCPR), which was also associated with an
increased risk of cardiovascular events (RR 2.80, 95% CI
2.40e3.27). Furthermore, the incidence of HAPR and HCPR
is signiﬁcantly higher in patients with chronic kidney dis-
ease and diabetes mellitus, both common risk factors in
PAOD.17,18
Platelet reactivity testing
Multiple tests are available for measuring platelet reactivity
(Table 2); the different tests measure diverse pathways of
thrombus formation and the reproducibility and applica-
bility vary strongly between these tests.19 To date, none of
the available tests has proven its superiority in predicting
thrombotic or bleeding events. However the VerifyNow, a
commercially available point of care test, shows congruent
results with the light transmittance aggregometer and is
widely studied in clinical trials.16
Personalized antiplatelet therapy
The association of HAPR and HCPR with increased risk of
thrombotic events sparked the concept of tailoring APT
based on platelet reactivity measurements. The basis of the
concept is that switching APT (to a higher dose or other
APT) with the aim of achieving lower platelet reactivity
would result in fewer thrombotic events, especially in high
risk patients, such as patients with diabetes mellitus or
renal failure. Multiple studies suggest that not only high
platelet reactivity (HPR) should be an indicator to adjust
APT, but that low platelet reactivity (LPR) should also be
considered as a reason to adapt APT due to the increased
risk of gastrointestinal and intracerebral bleeding compli-
cations.20,21 These data suggest the presence of a thera-
peutic window for platelet reactivity with HPR at one end
and LPR at the other end of the spectrum.
The data on HPR and LPR might elicit the idea that simply
testing platelet reactivity in response to antiplatelet agents
and adjusting the regimen based on the results will lead to
improved clinical outcomes. However, the clinical beneﬁt of
tailoring APT based on platelet function tests in patients
undergoing PCI has shown disappointing results thus far.
Two major trials (GRAVITAS, n ¼ 2,21422 and ARCTIC,
n ¼ 24023) showed no difference in their primary composite
endpoint (death of cardiovascular causes, non-fatal acute
myocardial infarction, and ST elevation) or bleeding com-
plications after 6 months in GRAVITAS and 1 year in ARCTIC,
when comparing standard APT with tailored APT. However,
a few smaller studies showed a beneﬁcial effect of tailoredversus standard APT on a composite endpoint (e.g. cardiac
death, stent thrombosis, recurrent ACS, recurrent PCI <1
year) without any difference in bleeding complications.24e27
The two largest trials included a low risk population,
counteracted HPR primarily with a higher dose of the same
APT instead of switching APT, and used a single platelet
reactivity test, which could have resulted in the lack of ef-
fect of tailored APT.PAPT in patients with PAOD
Most research regarding personalized antiplatelet therapy
(PAPT) has been performed in patients with coronary artery
disease (CAD) undergoing PCI. Randomized controlled trials
to investigate the potential beneﬁt of PAPT in patients with
PAOD are mandatory. However, several questions need to
be answered before this treatment strategy can be imple-
mented in clinical trials.28
1. What is the incidence of HAPR and HCPR in patients
with PAOD?
2. Is high and low platelet reactivity in patients with PAOD
related to the occurrence of respectively thrombotic or
bleeding events during follow up?
3. What are the optimal cut off values of different platelet
reactivity tests to predict thrombotic or bleeding
events?
3. Does HPR change over time and what is the optimal
moment for platelet reactivity testing?
4. What is the optimal alternative APT for patients with
PAOD displaying HAPR or HCPR?
Importantly, low patency rates after PTA leave room for
randomized controlled trials to prove signiﬁcant beneﬁt of
PAPT compared with standard care after the questions
above are answered. Since the risk of hemorrhagic com-
plications might increase with the use of novel and dual
APT, the use of a combined clinical beneﬁt endpoint,
comprising both thrombotic and bleeding events, would be
advised in potential future trials.CONCLUSION
Technological improvements in the endovascular arma-
mentarium have made increasingly complex atherosclerotic
lesions eligible for endovascular interventions, which has
led to a mainly endovascular ﬁrst strategy in PAOD. How-
ever, the patency rates of endovascular procedures still
leave room for improvement and optimization of post-
procedural medical therapy, including personalized APT, is
therefore essential. Current evidence regarding the optimal
APT after peripheral endovascular revascularization is
inconclusive. It is reasonable to expect that personalized
APT, based on platelet reactivity measurements, may
improve outcomes. However, some important conditions
should be fulﬁlled prior to routine implementation of
personalized APT in clinical practice, such as determination
of the optimal platelet reactivity test, and the optimal type
and duration of (D)APT.
Table 2. Commonly used platelet reactivity test.
Platelet reactivity testing Technique Pros Cons
VerifyNow Platelets are stimulated with agonists,
causing platelet activation and
precipitating to the ﬁbrinogen coated
beats in the cartridges. Degree of platelet
is based on remaining optical light
transmittance through the cartridges
Easy and rapid point of care test
Aspirin, P2Y12, and GPIIb/IIIa inhibitor
monitoring
Cut off values differ per patient population
Low correlation with golden standard
(LTA)
Light transmittance aggregometry (LTA) Citrated whole blood is centrifuged,
resulting PRP and PPP. After stimulation of
the platelets with agonists, formed
aggregates modify optical density of the
samples, expressed as % platelet
aggregation
Gold standard due to long lasting
experience
Manually conducted test therefore
reproducibility between laboratories is low
Time consuming
Platelet function analyzer (PFA) Blood is aspirated at high shear rates
through cartridges with either collagen
and epinephrine or collagen and ADP,
which induce platelet adhesion, activation
and aggregation. This leads to rapid
occlusion of the aperture and cessation of
blood ﬂow, deﬁned as closure time
Rapid and automatic Originally designed as screening
instrument for thrombopathy and thus
better standardized compared to
monitoring of APT
Multiplate Activated platelets, after stimulation with
agonists, adhere to metal sensor wires and
electrical resistance increases
Aspirin and P2Y12 monitoring Semi-automatic; preparation of the
agonists and pipetting is necessary to
perform the tests
Vasodilator stimulated phosphoprotein
(VASP)-phosphorylation assay
ADP inhibits VASP (an intracellular platelet
protein) phosphorylation through the
P2Y12 receptor. Persistent VASP
phosphorylation, as measured with ﬂow
cytometry, correlates with P2Y12 receptor
inhibition, reﬂecting the effect of the
P2Y12 inhibitor
Standardized kit Only applicable for monitoring of P2Y12
inhibitors
Time consuming
ADP ¼ adenosinediphosphate; APT ¼ antiplatelet therapy; PRP ¼ platelet rich plasma; PPP ¼ platelet poor plasma.
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be overcome prior to routine implementation, the concept
of individualized medicine regarding the type of endovas-
cular intervention is advocated, but foremost post-
procedural APT in patients with PAOD to optimize the re-
sults of endovascular interventions, as apparent from the
presented case.CONFLICT OF INTEREST
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